New Healthcare research report from Business Monitor International is now available from Fast Market Research

[USPRwire, Wed Mar 23 2016] Bahrain's government will continue in its attempts to attract investments and expand domestic pharmaceutical manufacturing. Although there will be an expansion of local drug production, foreign drugmakers will continue to view Bahrain as an unattractive option for expansion. Instead, these firms will opt to develop their manufacturing capabilities in the larger regional markets of Saudi Arabia and the United Arab Emirates.

Headline Expenditure Projections

Pharmaceuticals: BHD131mn (USD347mn) in 2015 to BHD140mn (USD372mn) in 2016; +7.2% in both local currency and US dollar terms. Forecast unchanged from last quarter.
Healthcare: BHD635mn (USD1.68bn) in 2015 to BHD688mn (USD1.82bn) in 2016; +8.4% in both local currency and US dollar terms. Forecast in line with last quarter.

Full Report Details at

Risk/Reward Index

In our Q216 matrix for the Middle East and Africa (MEA), Bahrain scores 52.0 out of 100, a slight improvement from last quarter's score of 51.8 and is ranked seventh out of the 31 markets surveyed in the region. The country's position is propped up by its favourable risks profile, as its longer-term rewards potential remains weighed down by its small population. On the other hand, Bahrain's well-developed business environment and demographic and epidemiological trends will continue to provide commercial opportunities for innovative drugmakers.

Latest Updates

In January 2016, Bahrain Pharma announced plans to expand its domestic manufacturing capabilities by means of three new joint ventures with investors from India, Kazakhstan and the Gulf Cooperation Council.

In January 2016, Bahrain's Health Minister and the Sri Lankan ambassador to Bahrain expressed the intention for increased cooperation between the two countries through the exchange of Sri Lankan medical expertise and field visits by consultant physicians specialized in micro medical disciplines.

Under the directives of the Supreme Council for Health chairman Lieutenant-General, Dr Shaikh Mohammed bin Abdulla Al Khalifa, a new committee has been set up in Bahrain to monitor applications for registrations of medicines in the country.

In December 2015, Dubai-based Aster DM Healthcare opened a medical facility in Bahrain as part of plans to expand its presence in the Gulf with investments over USD136mn during the next two years.

BMI Economic View

Weaker government spending will have an adverse impact on Bahrain's economy, with growth set to slow to 2.9% in real terms in 2016. That said, a well diversified economic base, trade and financial linkages with the rest of the Gulf and - over the longer term - the coming on stream of new industrial projects will help to support growth.

BMI Political View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Oman Pharmaceuticals & Healthcare Report Q2 2016
- Iraq Pharmaceuticals & Healthcare Report Q2 2016
- Estonia Pharmaceuticals & Healthcare Report Q2 2016
- Latvia Pharmaceuticals & Healthcare Report Q2 2016
- Egypt Pharmaceuticals & Healthcare Report Q2 2016

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »